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Abstract
Background: Prostate cancer is the most frequently diagnosed cancer in American men, and few
effective treatment options are available to patients who develop hormone-refractory prostate
cancer. The molecular changes that occur to allow prostate cells to proliferate in the absence of
androgens are not fully understood.
Results: Subtractive hybridization experiments performed with samples from an in vivo model of
hormonal progression identified 25 expressed sequences representing novel human transcripts.
Intriguingly, these 25 sequences have small open-reading frames and are not highly conserved
through evolution, suggesting many of these novel expressed sequences may be derived from
untranslated regions of novel transcripts or from non-coding transcripts. Examination of a large
metalibrary of human Serial Analysis of Gene Expression (SAGE) tags demonstrated that only three
of these novel sequences had been previously detected. RT-PCR experiments confirmed that the
6 sequences tested were expressed in specific human tissues, as well as in clinical samples of
prostate cancer. Further RT-PCR experiments for five of these fragments indicated they originated
from large untranslated regions of unannotated transcripts.
Conclusion: This study underlines the value of using complementary techniques in the annotation
of the human genome. The tissue-specific expression of 4 of the 6 clones tested indicates the
expression of these novel transcripts is tightly regulated, and future work will determine the
possible role(s) these novel transcripts may play in the progression of prostate cancer.
Background
Prostate cancer is the most frequently diagnosed cancer as
well as the second leading cause of cancer death among
American men [1]. Androgen ablation therapy for patients
with advanced prostate cancer inevitably fails as the dis-
ease progresses to an androgen-independent stage [2].
Few effective treatment options are available to these
patients, and these increase survival by only a matter of
months [3,4]. We examined an in vivo human prostate
cancer tumour model to identify the underlying molecu-
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lar events involved in hormonal progression. The LNCaP
hollow fibre model differs from xenograft models by
growing the LNCaP human prostate cancer cell line
within fibres that are implanted subcutaneously in host
mice [5]. These fibres prevent host cells from infiltrating,
and contaminating, the tumour cell population. Upon
castration of the host the LNCaP cells progress to an
androgen-independent stage as determined by a rising
titre of serum prostate-specific antigen (PSA), mimicking
this aspect of clinical disease [5].
Many genes important in the development and progres-
sion of cancer have been identified by first detecting their
altered expression at different stages of the disease. It has
thus become desirable to perform high-throughput gene
expression analyses to quickly assay the expression status
of large numbers of genes in a given model or treatment
condition. A variety of techniques are available for moni-
toring gene expression profiles, with microarrays and
Serial Analysis of Gene Expression (SAGE) being the most
widely used. However, microarray experiments are only
able to monitor the expression of genes for which prior
knowledge of the transcript sequence is available, and
they also lack the sensitivity to detect transcripts expressed
at very low levels. The SAGE technique is capable of
detecting novel transcripts [6-9], but SAGE is also not
optimal for detecting low abundance transcripts. In con-
trast, suppression subtractive hybridization includes a
normalization step that enriches for rare transcripts in a
population of RNAs [10,11]. Subtractive hybridization is
also able to detect entirely novel transcripts for which no
previous annotation exists [12,13]. Thus, subtractive
hybridization is a powerful tool to detect less abundant
transcripts and the novel transcripts that tend to be
expressed at low levels. In support of this concept, a signif-
icant proportion of the transcripts identified by subtrac-
tive hybridization were shown to be expressed at levels
below the detection limit of Affymetrix GeneChip® arrays
[14]. Additionally, subtractive hybridization identified a
number of novel transcripts which were not represented
on these arrays [14].
Gene expression changes occurring with the hormonal
progression of prostate cancer have been examined in var-
ious systems (see [15-17], for example). Our goal was to
utilize the LNCaP hollow fibre model to identify genes
that had not been previously associated with prostate can-
cer. The application of subtractive hybridization resulted
in the identification of a number of novel expressed
sequences in this model. These sequences exhibit low pro-
tein-coding potential and low conservation across species,
but RT-PCR experiments confirmed their expression in
samples of prostate cancer and in a variety of human tis-
sues.
Results
Novel transcripts were represented in the subtracted 
cDNA libraries
Suppression subtractive hybridization was used to isolate
novel transcripts expressed at different stages of hormonal
progression in the LNCaP hollow fibre model. This model
enables the isolation and molecular analysis of prostate
cells (free from contamination by host cells) at multiple
stages of hormonal progression. Samples from intact
mice, from mice 10 days after castration (at PSA nadir),
and mice 45–60 days post-castration were used as the
tester and driver samples in independent subtractive
hybridization experiments. Each experiment compared
different time points, and both forward and reverse sub-
tractions were performed for each comparison.
To identify novel genes associated with prostate cancer we
examined the sequences of all 428 of the subtracted
clones isolated from our subtractive hybridization experi-
ments. These sequences were filtered to remove poor
quality sequences and any clones containing less than 25
bp of sequence, more than one insert, or regions of repet-
itive sequence (Table 1). Of the remaining 340 clones,
103 clones contained inserts that were represented by
other clones in the library. BLAST analysis of the Ensembl
database (v. 35 – Nov 2005) [18] was then used to iden-
tify the transcript represented in each of the remaining
237 nonredundant clones. First, the clones were searched
against the population of annotated Ensembl cDNAs,
identifying 150 clones (63.3%) derived from previously
annotated human cDNAs (Fig. 1). The remaining 87
clones were then mapped to the human genome using the
Ensembl database, with all mappings verified using the
UCSC Human Genome Browser (hg17 – May 2004) [19]
and GenBank databases. This search identified 57 clones
(24.1%) matching expressed sequence tags (EST) and
mRNAs which had not yet been classified as Ensembl
cDNAs. A clone exhibiting any overlap with a transcript
was considered to be part of that transcript. Of the 30
remaining clones, 5 (2.1%) did not align uniquely to the
genome, but the other 25 (10.5%) did map uniquely to
unannotated regions of the human genome and were con-
sidered to represent novel transcripts (Fig. 1). These 25
clones mapped to a variety of locations, including within
introns of annotated transcripts, nearby annotated tran-
scripts, as well as intergenic regions. This analysis sug-
gested that novel transcripts were represented in our
subtractive hybridization libraries.
Characterization of novel clone sequences
We next assessed the sequence characteristics of these
novel clones to determine if there were differences
between those mapping to unannotated regions of the
genome relative to those clones mapping to known tran-
scripts. Five characteristics were examined for each clone:BMC Genomics 2007, 8:32 http://www.biomedcentral.com/1471-2164/8/32
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(1) their protein coding potential, (2) their evolutionary
conservation, (3) whether they showed evidence of splic-
ing, (4) whether they demonstrated homology to known
non-coding RNAs, and (5) whether they contained a poly-
adenylation site. For this analysis, the 25 novel clones
(Table 2) were compared to 25 clones randomly chosen
from the 57 that mapped to previously identified ESTs
(Table 3), and another 25 clones randomly chosen from
Distribution of sequence matches in the suppression subtractive hybridization clone set Figure 1
Distribution of sequence matches in the suppression subtractive hybridization clone set. The 237 non-redundant 
clones identified through sequence analysis of the subtractive hybridization libraries were mapped to the human genome (v. 35) 
and classified as representing an annotated Ensembl cDNA, a previously identified expressed sequence tag (EST), or an unan-
notated region of the genome. Clones not mapping uniquely to the genome were classified as ambiguous matches.
Ambiguous
2.1%
Unannotated
10.5%
EST
24.1%
Annotated 
63.3%
Table 1: Summary of sequenced cDNA clones
Total (%)
Total sequenced clones 428
Mouse 24 (5.6)
Multiple inserts 10 (2.3)
Poor quality 54 (12.6)
Redundant 103 (24.1)
Remaining Nonredundant 237 (55.4)BMC Genomics 2007, 8:32 http://www.biomedcentral.com/1471-2164/8/32
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the 150 mapping to annotated transcripts (Table 4). First,
to assess the likely coding potential of each clone, the
length of the longest open reading frame (ORF) was deter-
mined using the ORF Finder tool at NCBI. The clones
derived from known transcripts were much more likely to
contain an ORF spanning most of the sequence. It should
also be noted that the sequences used for this analysis
were derived from single-pass sequencing reads, and thus
potential sequencing errors may interrupt longer ORFs.
Next, we qualitatively assessed the degree of conservation
of each of these clones using the Vertebrate and Multiz
Alignment and Conservation track at UCSC [20]. This
track provides a measure of evolutionary conservation of
a genomic region amongst 17 vertebrate species. As pre-
dicted, clones originating from known transcripts tended
to show high conservation of their respective genomic
loci, while the clones representing novel transcripts
mapped to regions of the genome that were poorly con-
served. This was consistent with the prediction that highly
conserved transcripts would be expressed by a larger
number of species, thus increasing the likelihood of the
transcript having been detected in previous studies.
We were also interested in whether these sequenced
clones derived from spliced regions of transcripts. While
over half of the annotated clones appeared to be spliced,
only one clone matching an EST was spliced, and none of
the novel clones showed evidence of splicing. It may be
that the clones matching ESTs and unannotated regions
were more frequently derived from untranslated regions
of transcripts. This would be consistent with the decreased
size and number of ORFs in these clones. A number of
families of non-coding RNAs have also now been identi-
fied, such as ribosomal RNAs, transfer RNAs, and more
recently, micro RNAs. To determine if the unannotated
sequences identified here may be non-coding RNAs, these
sequences were queried against the Rfam database of non-
coding RNA families [21]. None of the novel sequences
displayed homology to any of the known RNA families in
this database. Next we examined all these clones for the
presence of poly-adenylation sites. Approximately 30% of
all clones, regardless of their mapping, were poly-ade-
nylated, further supporting that the novel clones were
derived from mRNA transcripts. This result also showed
that the known and novel transcript fragments were
equally likely to contain poly-adenylation sites, suggest-
ing that novel clones were not specifically biased towards
the 3' untranslated regions of transcripts.
Analysis of SAGE tags in the novel clones
SAGE is a second technique that has been used to identify
large numbers of novel transcripts [6,7]. We sought to
determine if the 25 novel clones had been previously
detected in SAGE experiments performed with human tis-
sues. Subtracted clones matching unannotated regions of
the human genome were searched for potential NlaIII
restriction sites and the 17 bp of downstream sequence
was considered to represent a LongSAGE tag. Twenty of
Table 2: Sequence characteristics of unannotated clones
Clone Accession Length 
(bp)
ORF 
(%)*
Degree of 
Conservation
Spliced polyA Nearest SAGE Tag Distance to 
SAGE (kb)
Chromosome 
Position
Description
11_B09 DQ668378 306 25.2 +† no no CCAATCTTTAACTTCCT 8.3 2q31.3 100 kb from mRNA AK000023
11_E05 DQ668379 1338 8.1 + no no GCATTTTATTTTTTAAG 1.9 15q11.2 4 kb from mRNA AL832227
12_A03 DQ668380 543 46.8 + no no GTTCTCTGATTCCTAAG 14.5 2q31.3 50 kb from EST CF140309
12_A06 DQ668381 324 39.2 + no no TGCAGGAGACTAGCAAG 11.6 2q32.3 Intron of TMEFF2
12_E10 DQ668383 576 46.7 + no no No tag in clone N/A 22q13.2 8 kb from mRNA BX648018
13_F09 DQ668384 454 50.7 + no yes AGCCTCCTCCTCTCCTT 6.4 21q21.1 Intron of NCAM2
13_G01 DQ668385 261 41.0 + no yes ATTTTCATTGCTTTTAT 7.2 18q22.3 Intron of NETO1
13_G06 DQ668386 389 32.1 + no yes GAACAAAGACAGATATG 2.0 8q22.3 Intron of GRHL2
14_D01 DQ668387 134 77.6 +++ no no ATTTTATGGTTATTATT 8.7 3p14.2 Intron of FHIT
1a_A04 EC093934 245 25.3 + no no No tag in clone N/A 21q21.1 Intron of NCAM2
1a_C02 DQ668388 1853 12.4 ++ no no TCTTACTTTTTCATTAG 2.2 5q23.1 Intron of TNFAIP8
1a_E09 DQ668389 796 29.5 + no no TCAGATTTTGGATATCC 1.9 10p12.31 Intron of NEBL
1b_C12 DQ668390 555 16.8 + no no GGATGGGATCAAGAGAG 17.5 14q12 Intron of PRKD1
1c_D03 DQ668391 292 18.5 + no no No tag in clone N/A 21q21.1 Intron of NCAM2
1c_E10 DQ668392 679 14.9 + no no TACTTACGATTTTTCAG 0.0 8q22.1 Intron of DKFZp779L1068
1c_F02 DQ668393 475 26.7 + no no TTCTAGCTCCATTGACT 1.8 8p11.22 Intron of ADAM2
1d_E01 DQ668394 771 26.7 + no no TATACAACTGTAGATGC 0.15 16q12.1 Intron of CDA08
1d_F04 DQ668395 465 21.9 +++ no yes No tag in clone N/A 5q21.3 Intron of EFNA5
2c_A06 EC094025 658 10.8 ++ no no No tag in clone N/A 20p12.1 Intron of DSTN
2c_C10 DQ668396 371 28.0 ++ no yes TTCTAGCTCCATTGACT 6.4 8p11.22 Intron of ADAM2
2c_G10 DQ668397 969 19.8 + no no TCAATGGAGGATGATAG 0.24 4q23 Intron of PPP3CA
2d_B01 DQ668398 1100 15.2 + no no GAATCTGGATAAAGACT 0.0 10q21.1 87 kb from EST BG194644
2d_D06 DQ668399 598 37.0 + no yes TTGTAACAAGTTAGTAA 0.0 12p13.2 Intron of mRNA K03207
2d_D09 EC094055 627 26.6 + no no GCAACACTGCACTCCAG 8.8 12q21.31 Intron of PPFIA2
2d_E01 DQ668400 722 34.8 + no no CAGAAAAAACAAAACAG 23.2 8q24.23 Intron of EST BQ226050
* Length of longest open reading frame as a percentage of the total length of each clone.
† Degree of conservation of each clone: + = 0–9%; ++ = 10–29%; +++ = 30–59%; ++++ = 60–79%; and +++++ = 80–100% conservation.BMC Genomics 2007, 8:32 http://www.biomedcentral.com/1471-2164/8/32
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our unannotated sequences contained uniquely mapping
regions which could be potential LongSAGE tags, and
many clones contained multiple possible tags. We then
compared our predicted LongSAGE tags to a metalibrary
containing approximately 11 million uniquely mapping
human SAGE tags previously identified at the B.C. Cancer
Agency Genome Sciences Centre or in the Cancer Genome
Anatomy Project (CGAP) at NCBI. These tags were identi-
fied in 79 SAGE libraries representing a variety of human
tissues, including embryonic and haematopoietic stem
cells, samples of normal and cancerous lung, brain, pan-
creas, breast and colon, as well as some human cancer cell
lines. Only three of the 20 unannotated clones contained
LongSAGE tags that were previously detected in a SAGE
experiment (Table 2); none of these tags mapped to anno-
tated transcripts. These tags, from clones 1cE10, 2dB01,
and 2dD06, occurred once, thrice, and once, respectively,
in the entire human LongSAGE metalibrary, providing in
silico evidence that these clones represent novel transcripts
that are expressed at very low levels.
A LongSAGE tag and a novel clone may also derive from
the same transcript without the two sequences directly
overlapping. We therefore looked for LongSAGE tags
mapping to the 50 kb of genomic DNA sequence flanking
our novel sequences to identify any neighbouring regions
predicted to be expressed based on the previous SAGE
experiments. The genomic neighbourhoods of all 20 of
the analyzed subtracted clones contained LongSAGE tags
that were not from annotated transcripts. As stated above,
3 of these clones mapped directly to a LongSAGE tag. Of
the remaining 17 clones, 7 mapped within 2.5 kb of a pre-
viously detected LongSAGE tag, while the remaining 10
clones were up to 23 kb from their nearest tag. These tags
also occurred at low frequency in the human metalibrary,
with each tag being detected from one to three times.
These regions of the genome do not appear to encode
abundantly expressed transcripts, providing a possible
explanation why these transcripts were not detected previ-
ously. This analysis supported the concept that our novel
subtracted clones were likely to represent entirely novel
transcripts.
The novel subtracted clones are expressed by a variety of 
cell types
To confirm that the novel clones detected by subtractive
hybridization are naturally expressed in cells we per-
formed a series of RT-PCR experiments. We chose 6 novel
clones and examined their expression in LNCaP cells from
the hollow fibre model. All six of the chosen clones were
clearly expressed in LNCaP cells (Fig. 2A). The absence of
bands in the reverse transcriptase (RT)-negative samples
Table 3: Sequence characteristics of clones matching previously identified ESTs
Clone Accession Length (bp) ORF (%)* Degree of Conservation Spliced polyA
11_C08 EC093853 470 19.6 +† no no
13_F07 EC093910 281 44.5 + no yes
13_G08 EC093913 126 75.4 + no no
14_D02 EC093923 671 27.6 + no no
14_G04 EC093933 521 42.4 + no no
1a_B02 EC093936 579 25.7 + no no
1a_D01 EC093941 451 20.4 ++ no no
1a_F05 EC093946 478 19.9 +++++ no yes
1a_H09 EC093956 683 33.7 + no no
1b_A09 EC093959 619 30.4 ++ no no
1b_A11 EC093961 284 63.0 + no yes
1b_C01 EC093963 584 27.9 + no no
1c_A02 EC093968 514 25.5 ++ no yes
1c_D12 EC093979 215 59.5 +++++ no no
1c_E05 EC093980 429 49.4 + yes yes
1c_G06 EC093989 525 26.1 + no no
1d_C12 EC094007 596 22.0 ++ no yes
1d_G02 EC094018 351 36.5 +++++ no no
2c_B04 EC094028 484 21.5 + no yes
2c_B10 EC094032 427 44.0 + no no
2c_D10 EC094037 487 37.0 + no no
2c_F04 EC094043 384 45.8 + no yes
2c_H03 EC094044 642 48.0 + no no
2d_B10 EC094049 299 54.8 +++ no no
2d_D07 EC094054 299 60.5 + no no
* Length of longest open reading frame as a percentage of the total length of each clone.
† Degree of conservation of each clone: + = 0–9%; ++ = 10–29%; +++ = 30–59%; ++++ = 60–79%; and +++++ = 80–100% conservation.BMC Genomics 2007, 8:32 http://www.biomedcentral.com/1471-2164/8/32
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confirmed that these products did not derive from con-
tamination with genomic DNA. The tested clones
included two clones containing a previously identified
LongSAGE tag, three clones for which the nearest tag was
between 2 to 8 kb away, and one clone that was approxi-
mately 14 kb from the nearest LongSAGE tag. Thus, the
novel transcript fragments isolated here were derived from
expressed transcripts that had not previously been docu-
mented in any database.
To determine the presence or absence of these novel tran-
scripts in various tissues we performed RT-PCR with a
panel of RNAs derived from "normal" human tissues.
Each of the 6 clones chosen displayed unique tissue
expression profiles, with 4 clones being highly specific to
the prostate and testes or the testes alone, while the
remaining 2 clones were expressed in all the tissues tested
(Fig. 2B). Clone 2A03 was almost exclusively expressed in
the prostate, with only a faint product observed in the tes-
tes. Even the two clones observed in all the tissues tested
appeared to be expressed at variable levels in each of the
tissues. Thus, while the expression of some of these clones
appeared higher in LNCaP cells, the expression of these
novel sequences was not unique to this cell line.
Next we examined the expression of these 6 novel tran-
scripts in three samples of prostate cancer with matched
samples of "normal" prostate. While the cancer specimens
were not microdissected, these samples were all scored by
a pathologist to contain 65–80% tumour tissue. Five of
the transcripts were expressed in both the normal and can-
cer specimens (Fig. 2C). Clone 2dB01 showed the most
limited expression, being detectable in only one sample of
cancer. The expression of this transcript is quite limited as
LNCaP cells and the single cancer specimen were the only
non-testicular samples in which expression could be dem-
onstrated (Fig. 2B,C). While expression levels can not be
precisely measured via RT-PCR, some of these clones
appeared to show differential expression in the normal
samples relative to the cancer samples. From these exper-
iments we conclude that the novel clones derived from
our subtractive hybridization experiments in fact repre-
sent previously unannotated transcripts that are expressed
in a variety of human tissues.
Five of the novel clones are part of larger untranslated 
regions
The novel clones isolated here were cDNA fragments pre-
sumably derived from larger transcripts. We wanted to
Table 4: Sequence characteristics of clones matching Ensembl cDNAs
Clone Accession Length (bp) ORF (%)* Degree of Conservation Spliced polyA
11_F09 EC093861 149 100 +† no yes
11_G07 EC093866 169 86.4 ++++ yes no
11_G09 EC093868 323 43.3 ++ no yes
12_F01 EC093889 426 91.3 ++ yes no
12_F10 EC093893 276 74.6 ++++ yes no
12_G09 EC093898 279 49.1 ++ no no
12_G11 EC093899 433 73.2 +++++ yes yes
14_C11 EC093921 269 94.1 ++++ yes no
14_D07 EC093926 77 96.1 +++++ no no
14_E12 EC093929 318 43.1 ++++ no yes
14_F09 EC093932 180 100 +++ yes no
1a_B07 EC093937 477 69.0 +++++ yes yes
1a_E11 EC093945 655 33.7 ++++ yes no
1c_B12 EC093972 555 32.3 +++ yes yes
1c_D05 EC093975 325 27.4 +++ no yes
1c_D07 EC093977 425 37.9 ++ no no
1d_B08 EC094000 408 34.3 ++++ no no
1d_D04 EC094008 245 100 +++++ no no
1d_E07 EC094012 555 89.2 +++++ yes no
1d_E11 EC094014 670 60.6 ++ no yes
1d_F08 EC094016 297 91.9 +++++ yes no
1d_H01 EC094020 701 44.8 +++++ yes no
2c_B03 EC094027 92 100 +++++ yes no
2c_D08 EC094036 475 37.7 +++++ no no
2d_B03 EC094046 388 29.9 + no no
* Length of longest open reading frame as a percentage of the total length of each clone.
† Degree of conservation of each clone: + = 0–9%; ++ = 10–29%; +++ = 30–59%; ++++ = 60–79%; and +++++ = 80–100% conservation.BMC Genomics 2007, 8:32 http://www.biomedcentral.com/1471-2164/8/32
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isolate more sequence information from the full-length
transcripts to understand the possible functions of these
novel transcripts. The above analysis with the human
SAGE metalibrary identified a number of tags mapping
near the novel clones isolated using subtractive hybridiza-
tion, suggesting they may represent the same transcript.
RT-PCR experiments were then performed utilizing prim-
ers spanning clones 1E05 and 2dB01 and their neighbour-
ing LongSAGE tags. These experiments demonstrated that
some of these tags were in fact derived from larger tran-
scripts that also contained these novel subtracted clones
(Fig. 3). These PCR products were not detected in reverse
transcriptase negative samples, confirming they were not
derived from genomic DNA. Upon sequencing of these
PCR amplicons, clone 1E05 was demonstrated to be part
of an additional 6 kb untranslated region (accession nos.
DQ668402 and DQ668403) downstream of a previously
identified, but uncharacterized, mRNA represented in the
GenBank database (AL832227). Interestingly, mRNA
AL832227 was originally identified in human testis tissue.
This provides validation of the tissue expression profiles
we observed as clone 1E05 was only detected in cDNA
from testis (Fig. 2B). Finally, clone 2dB01 was part of a 1.6
kb transcript that did not contain any significant ORFs
(accession no. DQ668401). This transcribed region is
likely an untranslated region of a larger transcript that has
yet to be identified.
Rapid Amplification of cDNA Ends (RACE) was then per-
formed in an attempt to isolate full-length transcripts for
the remaining four clones. RACE in the 3' direction suc-
cessfully extended clones 1B09, 2A03, and 1aC02 (acces-
sion nos. EH613608 – EH613610) to poly-adenylation
sites. Unfortunately, RACE in the 5' direction did not yield
larger transcript fragments for any of these clones. In all,
these experiments have isolated approximately 0.9 kb of
transcript 1B09, 1.5 kb of transcript 2A03, and 2.5 kb of
transcript 1aC02, indicating they too encode large non-
coding regions of novel transcripts.
Discussion
While the precise number of genes in the human genome
remains unknown, it is clear that an even greater number
of transcripts are produced by a myriad of alternative
splicing events. The recognition of non-coding RNAs has
also resulted in a greater focus on transcripts not contain-
ing open reading frames. Thus, even with the completed
sequence of the genome further experiments are required
to fully annotate the functional units transcribed from the
genome in the different cell types during normal growth
and development, as well as in diseased tissues. High-res-
olution tiling microarrays have been used to generate pre-
dictions of likely transcripts, many of which mapped to
intergenic and intronic regions of the genome that were
not previously annotated [22-24]. Similarly, approaches
focused on sequencing full-length cDNAs continue to
identify a large number of novel transcripts, many of
which appear to be non-protein coding [25,26]. Our
The novel subtracted clones were expressed in a variety of  human tissues Figure 2
The novel subtracted clones were expressed in a 
variety of human tissues. (A) RT-PCR was performed 
with primer pairs specific for each of six novel clones using 
cDNA from the LNCaP hollow fibre model. RT indicates the 
presence or absence of Reverse Transcriptase. (B) RT-PCR 
was performed using cDNAs generated from normal human 
tissues with each of the six novel clones. All clones were 
expressed in at least one of the normal tissues. (C) RT-PCR 
was performed using cDNAs generated from three samples 
of prostate cancer (T1 – T3) and their respective matched 
normal samples (N1 – N3). All six of the clones were 
expressed in at least one of these samples.
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results here provide further evidence that a significant
number of genes and transcripts remain to be identified.
Studies now suggest that the majority of the human
genome is transcribed, but the function(s) of most of
these transcripts has not yet been demonstrated (reviewed
in [27]). The lack of defined function for these transcripts
has led some to propose that they arise indirectly through
spurious transcription of the genome. However, new
functions of non-coding transcripts continue to be identi-
fied, indicating that these "spurious" transcripts likely
have functions that have yet to be characterized. For exam-
ple, steroid receptor RNA activator (SRA) was demon-
strated to act as an RNA transcript to regulate the
transcriptional activity of steroid nuclear receptors,
including the androgen receptor [28]. Another non-cod-
ing transcript, expressed at low levels in various tissues,
was recently demonstrated to regulate the nuclear traffick-
ing of nuclear factor of T cells (NFAT), and has been
renamed non-coding RNA repressor of NFAT (NRON)
[29]. Such studies confirm that low-abundance, non-cod-
ing, RNA transcripts perform diverse functions and regu-
late multiple biological processes.
Subtractive hybridization has been used to characterize
gene expression changes associated with prostate cancer
[12,15,30-33], and some of these studies have also char-
acterized novel genes that were identified from their sub-
tracted libraries [12,13,30]. However, these reports
examined only a few novel genes that were differentially
expressed in their experimental systems, and few studies
have used subtractive hybridization to examine changes
with hormonal progression in an in vivo model [15]. Our
study is unique in that we sequenced all the clones arising
from the subtractive hybridization experiments per-
formed with in vivo samples from the LNCaP hollow fibre
model. This approach identified a large number of tran-
scripts that had not previously been detected in prostate
cancer cells and may be of prognostic or therapeutic value.
We identified 25 completely unannotated clones, and an
additional 57 clones matching previously sequenced ESTs
that were otherwise unannotated. The isolation of these
ESTs specifically from prostate cancer cells may prove
informative at a later date. Furthermore, we considered
any overlap of an EST or annotated gene with one of our
clones to signify that that clone derived from a previously
identified transcript. However, several of the clones
matching ESTs and annotated transcripts displayed only
partial overlap with the known sequence, suggesting that
the subtracted clone may still represent an unidentified
splice variant of the known transcript. Most of these novel
transcript fragments exhibited low sequence conservation
amongst vertebrate species, though this may indicate that
these transcripts are human- or primate-specific. Prostate
cancer is only known to spontaneously occur in humans,
rats, and some species of dogs even though the prostate
organ is present in all mammals. Furthermore, the human
prostate exhibits numerous morphological differences.
Thus, it is likely that many transcripts required for prostate
development and prostate cancer progression would not
be extensively conserved throughout evolution. In sup-
port of this, the KLK3  gene, encoding prostate-specific
Two of the novel clones were part of transcripts containing a  neighbouring SAGE tag Figure 3
Two of the novel clones were part of transcripts con-
taining a neighbouring SAGE tag. RT-PCR amplified 
transcript regions between clones 1E05 (A) and 2dB01 (B) 
and SAGE tags identified nearby each clone. RT indicates the 
presence or absence of Reverse Transcriptase.
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antigen (PSA), is only present in primate genomes [34];
PSA is a well known clinical marker used to monitor pros-
tate cancer progression and response to therapy. This
demonstrates that evolutionary conservation alone is not
predictive of potential clinical utility.
The functional relevance of these novel transcripts in the
hormonal progression of prostate cancer remains to be
elucidated. In our experiments, 4 of the 6 clones tested
were expressed only in the normal prostate and testes; this
limited tissue expression profile suggests these novel tran-
scripts may function specifically in these organs. This also
suggests the expression of these transcripts is tightly regu-
lated, as would be expected for a functional transcript.
Furthermore, a related publication from our group identi-
fied a novel variant of TMEFF2 which encodes a secreted
form of the protein [35]. This alternate form of the protein
was identified after a novel clone from our subtractive
hybridization library (clone 2A06) was mapped to the
fourth intron of the TMEFF2  gene. The expression of
TMEFF2 has been shown to increase with progression to
androgen independence [15,36], consistent with our sub-
tractive hybridization experiments. TMEFF2 is also cur-
rently being investigated as a target for antibody-based
therapy in the treatment of prostate cancer [37,38], con-
firming that our approach identified novel transcripts
which may be of interest in the study of prostate cancer.
Changes in expression of some of these transcripts may
also be valuable as a marker for disease progression.
To characterize the function(s) of these novel transcripts it
will first be necessary to identify the full-length cDNA
sequence. Multiple techniques are available to recover
full-length cDNA molecules starting from only cDNA frag-
ments. For example, RACE is widely used to obtain full-
length cDNA sequences [39]. RACE was successful in iso-
lating further 3' sequence information for 3 of the 4 clones
for which it was attempted. As in the case of clone 1E05,
it is possible that all three of these clones actually derive
from large 3' untranslated regions of protein coding tran-
scripts. The large size and low expression levels of these
transcripts increase the difficulty of identifying their full 5'
sequence. Alternatively, we may have already identified
the majority of the sequence in these novel, non-coding
transcripts. Another technique to identify full-length
sequence for these novel transcripts would be to screen
existing cDNA libraries [6,13]. However, given the rela-
tively low expression of these transcripts this approach
would likely require extensive screening of such libraries.
Two recent studies have used Northern blot analysis to
detect expression of similar low-abundance, non-coding,
novel transcripts [22,26]. These groups found that only
20–30% of the novel transcripts were detectable by North-
ern blot analysis, even when using large amounts of poly-
A+ RNA, indicating that the remaining transcripts fell
below the detection limit of this technique.
Margulies et al. [40] recently described a highly parallel
sequencing by synthesis approach that demonstrated an
increased throughput for sequencing of genomic DNA.
Our group has combined sequencing by synthesis and
random shotgun analysis to generate ESTs and character-
ize the transcriptome of LNCaP cells grown in tissue cul-
ture [41]. This study isolated approximately 180,000 ESTs,
and of these, 1,900 (1.0%) mapped to the human genome
in regions not previously annotated in the Ensembl data-
base. One of these ESTs mapped directly to clone 2A03
described here, while 12 more mapped within 1.5 kb of
clones 1cD03 and 2dB01. However, the remaining 22
novel clones identified here were still not detected by this
alternative approach.
SAGE has also been used to identify potentially novel
transcripts [6-9]. Unfortunately, while SAGE provides suf-
ficient sequence information to accurately map the tags to
the human genome, there is often little other information
available to aid in the design of experiments to derive
more sequence data from these novel transcripts. In con-
trast, subtractive hybridization provides longer sequence
fragments, but it is not possible to determine the orienta-
tion of these fragments. Our data also suggest that subtrac-
tive hybridization was able to detect transcripts that had
not previously been found using SAGE or high through-
put sequencing by synthesis. It is possible that subtractive
hybridization may be more sensitive to detecting tran-
scripts expressed at low levels. Alternatively, subtractive
hybridization may isolate those transcripts that can not be
efficiently detected by SAGE, for instance transcripts lack-
ing an NlaIII restriction site. Common results from multi-
ple techniques gives greater confidence in the
identification of novel transcripts and underlines the
value of using complementary techniques to achieve a
more thorough analysis of the human transcriptome.
Conclusion
Our subtractive hybridization experiments have identified
novel transcripts that are specifically expressed in the
prostate and/or the urogenital tissues. It may be of clinical
value to further develop these novel transcripts as prog-
nostic or therapeutic markers for prostate cancer and hor-
monal progression. Additionally, characterizing such
novel transcripts and transcript variants may aid in identi-
fying and understanding the processes important in the
development of androgen independent disease.
Methods
Cell culture
LNCaP cells obtained from Dr. L.W.K. Chung (Emory
University School of Medicine, Atlanta, GA) were main-BMC Genomics 2007, 8:32 http://www.biomedcentral.com/1471-2164/8/32
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tained in RPMI 1640 supplemented with 5% (v/v) fetal
bovine serum (FBS) (HyClone, Logan, UT), 100 units/mL
penicillin, and 100 μg/μL streptomycin. All chemicals
were purchased from Sigma, unless stated otherwise.
LNCaP hollow fibre model
The LNCaP hollow fibre model has been described in
detail previously [5]. Briefly, LNCaP cells (2 × 107) in
RPMI 1640 with 20% (v/v) FBS were sealed inside polyvi-
nylidine fluoride (PVDF) fibres (500 kDa molecular
weight cutoff; 1 mm internal diameter; Spectrum Medical
Co, Houston, TX) and incubated overnight at 37°C. The
fibres were then cut into fragments of approximately 2 cm
and inserted subcutaneously into anesthetized male 6–8
week old athymic nude mice (BALB/c strain) obtained
from Charles River Laboratory (Montreal, Canada).
Serum samples were obtained from the dorsal tail vein of
mice every 7 days, and PSA levels measured by an immu-
noenzymatic assay (Abbott IMX, Montreal, Canada).
Serum samples were always obtained prior to the per-
formance of any procedure. After one week mice were cas-
trated by ligation of the vas deferens through a small
incision in the scrotum. Control (intact) animals were not
castrated, but all other procedures were performed on the
same schedule. Hollow fibres were removed on the day of
castration, 10 days post-castration, and 45–60 days post-
castration when serum PSA levels had risen. All fibres were
immediately placed on ice, washed three times in sterile
phosphate buffered saline (PBS), and wiped with sterile,
moistened lab wipes. Any fibre visibly contaminated by
mouse tissue was set aside. To harvest cells, 1 mL of ice-
cold TRIZOL® Reagent (Invitrogen, Burlington, Canada)
was flushed through the fibres and the cells homogenized
with a 21-G needle prior to storage at -80°C. All animal
procedures were performed according to protocols
approved by the Animal Care Committee at the University
of British Columbia.
Suppression subtractive hybridization
The SMART PCR cDNA Synthesis Kit (Clontech, Palo Alto,
CA) was used to generate full-length cDNA from 1 μg of
starting total RNA using oligo-dT primer according to the
manufacturer's protocol. Suppression subtractive hybridi-
zation was then performed with the PCR-Select™ cDNA
Subtraction Kit (Clontech) according to the manufac-
turer's protocol. Briefly, the cDNA was digested with RsaI
restriction endonuclease to generate fragments of approx-
imately equal lengths. The digested cDNA was purified
and split into two populations before ligation of Adaptor
1 or Adaptor 2R. An excess of driver cDNA was added to
each reaction, the DNA denatured, and hybridization per-
formed for 8 hours at 68°C. The two populations of
cDNA were then combined and fresh denatured driver
cDNA added before hybridizing for an additional 16
hours. The final cDNA population was subjected to two
rounds of PCR to specifically amplify the differentially
expressed cDNA transcripts. The efficiency of subtraction
was determined by monitoring levels of the housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) in these samples. The subtracted cDNA pools
were then ligated into pCR®2.1-TOPO vector (Invitrogen)
and transformed into competent bacteria. Positive colo-
nies were selected and their inserts sequenced unidirec-
tionally with T7 primer on an ABI 3700 automated
sequencer. Clones containing novel inserts were further
sequenced to obtain the entire insert sequence. All
sequences obtained in these experiments have been
deposited in dbEST [Accession numbers EC093848 –
EC094057; EH613608 – EH613610] and GenBank
[Accession numbers DQ668378 – DQ668403].
RT-PCR
Total RNA was isolated from LNCaP cells maintained in
vivo  using TRIZOL® Reagent according to the manufac-
turer's protocol. Total RNA samples from several human
tissues were purchased from Stratagene (La Jolla, CA).
Table 5: Primers used for RT-PCR
Clone Sequence (5'-3')
1B09 F CACAGGAGACCCTGTCTTACCT
R AAGCTCTTGCTAGGCATGTAGG
1E05 F AATAGATTGGCAGGCCTTTG
R TGGGATGAGCAGGATATCAA
2A03 F AGAGATGCAAACGGACGAAC
R TCACTTACTGGCTCCTGCAC
1AC02 F AAGGTTTCCATTGCATCAGG
R CCTGAAAGGCTGGTCTTCAA
2DB01 F CCACAACTTGGAAGCAATCA
R TTCCCTGTCCCCTAACTCCT
2DD06 F TGGCCATCATCAAGTCGATA
R GAGGGATGGTGAAATCACTG
GAPDH F CCGAGCCACATCGCTCAGA
R CCCAGCCTTCTCCATGGTGBMC Genomics 2007, 8:32 http://www.biomedcentral.com/1471-2164/8/32
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Samples of total RNA from cases of prostate cancer, and
their matched normal samples, were purchased from
Genomics Collaborative (Cambridge, MA). Reverse tran-
scription (RT) was performed using MMLV-RT (Invitro-
gen) with 1 μg of template RNA. Subsequent PCR
reactions were performed using 1 μL of the resulting
cDNA as template. The primers used to amplify the clones
are summarized in Table 5. PCR products of interest were
cloned into pCR®2.1-TOPO vector and sequenced by the
NAPS facility at the University of British Columbia.
RACE
Poly-A+ mRNA from LNCaP cells was used for RACE
experiments with the Smart RACE cDNA Amplification kit
(Clontech) according to the manufacturer's protocol. PCR
products were gel-purified, cloned, and sequenced.
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